Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086768 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Lei Zheng.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT07086768 is a Phase 1 study that is actively recruiting participants, run by Lei Zheng. The registered enrollment target is 57 participants.
The verdict
NCT07086768, a Phase 1 study, is actively recruiting participants, sponsored by Lei Zheng.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over time. In the second part of the study tow medications will be taken and the dose of the medication may be changed to a higher dose.
Interventions
- DRUG BSI-082
- OTHER Trastuzumab deruxtecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2026-01-26 |
| Est. Completion | 2028-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07086768
The ClinicalTrials.gov registry entry for NCT07086768 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lei Zheng, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BSI-082 is the first listed.
NCT07086768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07086768 about?
NCT07086768 is a clinical study titled "Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors". This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over ...
What is the current status of trial NCT07086768?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2026-01-26. Estimated completion is 2028-08-07.
What interventions are being tested in trial NCT07086768?
The interventions under investigation include: BSI-082 (DRUG), Trastuzumab deruxtecan (OTHER).
Who is sponsoring clinical trial NCT07086768?
This trial is sponsored by Lei Zheng, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.